Document is current
Any future updates will be listed below
-
Authors
Akiyama, Yuji https://orcid.org/0000-0001-5658-7419
Katai, Hitoshi
Kitabayashi, Ryo
Nunobe, Souya
Koeda, Keisuke
Yura, Masahiro
Sato, Yuya
Yoshikawa, Takaki
Terashima, Masanori
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP18ck0106317)
National Cancer Center Research and Development Funds (26-A-4, 29-A-3, 2020-J-3)
- License Information
-
More Information
Article History
Received: 6 December 2022
Accepted: 20 February 2023
First Online: 3 March 2023
Declarations
:
: HK reports the funding from National Cancer Center Research and Development Funds, and Japan Agency for Medical Research and Development. TY reports lecture fees from Chugai Pharmaceutical, Taiho Pharmaceutical, MSD, BMS, Daiichi Sankyo, Ono Pharmaceutical, Miyarisan Pharmaceutical, EA pharma, Astra Zeneca, and Terumo. MT reports the funding from Taiho Pharmaceutical, Chugai Pharmaceutical, Ono Pharmaceutical, Bristol Myers Squibb, Yakult Honsha, Takeda Pharmaceutical, Eli Lilly Japan KK, Pfizer Pharmaceutical, Daiichi Sankyo, Johnson and Johnson, Medtronic Japan, Intuitive Japan, Olympus. All the other authors declare no competing interests.
: All study procedures were conducted in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and the Declaration of Helsinki of 1964, and later versions. Informed consent or its substitute was obtained from all patients included in the study.
